Pharmacologic Management of Chronic Insomnia

First‑Line Non‑Pharmacologic Therapy

• Cognitive‑behavioral therapy for insomnia (CBT‑I) is the recommended first‑line treatment for chronic insomnia (American College of Physicians evidence report) 1.

Preferred Pharmacologic Agent

Eszopiclone (Lunesta)

• FDA‑approved for insomnia with demonstrated efficacy for up to 6 months; it improves both sleep onset latency and sleep maintenance in adults and older adults (strong evidence base) 1.
• Dose reduction is advised in women and adults ≥ 65 years because of slower drug clearance (moderate‑strength recommendation) 1.
• No clinically significant rebound insomnia is observed in the first three nights after discontinuation (low‑strength evidence) 1.
• Monitoring should include assessment for next‑day impairment, cognitive/behavioral changes, and complex sleep behaviors (moderate‑strength recommendation) 1.

Agents Not Recommended for Primary Insomnia

Trazodone (Desyrel)

• The 2020 VA/DoD guideline strongly recommends against using trazodone as monotherapy for chronic insomnia because systematic reviews show no meaningful improvement in objective sleep efficiency or total sleep time, and adverse‑effect risks outweigh limited benefits (strong recommendation) 2.
• The 2017 American Academy of Sleep Medicine guideline also advises against trazodone, noting that modest improvements in sleep latency (≈10 min) and total sleep time (≈22 min) are below clinically significant thresholds (moderate recommendation) 2.
• Trazodone is associated with a 2.3‑fold higher risk of discontinuation due to adverse effects and a 4.3‑fold higher rate of sleep‑related adverse effects compared with placebo (moderate‑strength evidence) 2.
• Common adverse effects include daytime drowsiness (~30 %), headache (~30 %), somnolence (~23 %), and in older adults an increased risk of falls, cognitive impairment, and severe hyponatremia (moderate‑strength evidence) 2.
• Trazodone is not FDA‑approved for insomnia; its use is off‑label (low‑strength evidence) 2.

Trazodone + Melatonin Combination

• No high‑quality randomized trials evaluate this combination for chronic insomnia, and existing retrospective data show no significant benefit (low‑strength evidence) 2.
• Therefore, the combination cannot be recommended over proven alternatives (moderate‑strength recommendation) 2.

Oxazepam (Serax) and Other Benzodiazepine Hypnotics

• Evidence for benzodiazepine hypnotics in insomnia is insufficient or of low strength; they are not recommended because of high abuse potential and the availability of safer, more effective alternatives (low‑strength recommendation) 1.
• Observational studies link hypnotic use (including benzodiazepines) with increased risk of dementia, fractures, and major injury (moderate‑strength evidence) 1.
• Oxazepam lacks FDA approval for insomnia and has no supporting efficacy data for sleep maintenance (low‑strength evidence) 1.

Safety and Tolerability Considerations

Population‑Specific Recommendations

• Adults < 65 years with sleep‑onset and sleep‑maintenance problems:

  • Use eszopiclone 2–3 mg at bedtime (dose may be reduced based on tolerability).
  • Avoid trazodone monotherapy (see above).

• Adults ≥ 65 years:

  • Use eszopiclone 1–2 mg at bedtime (lower dose proven effective).
  • Consider controlled‑release melatonin 2 mg as a first‑line option.
  • Avoid benzodiazepines (including oxazepam) due to fall and cognitive risks.

• Patients with comorbid depression:

  • Eszopiclone remains the preferred insomnia treatment.
  • If trazodone is used for depression (not insomnia), start 50–150 mg one hour before bedtime with food, reassess within 2–4 weeks, and discontinue if no objective sleep benefit is observed (off‑label use) 2.

Duration of Therapy and Monitoring

• Limit eszopiclone to the shortest effective duration; efficacy has been demonstrated up to 6 months, but regular reassessment is advised (moderate recommendation) 1.
• If Z‑drugs (e.g., zopiclone) are used, restrict to ≤ 4 weeks and taper gradually (10–25 % dose reduction weekly) to minimize dependence risk (moderate recommendation) – note that this recommendation is based on regional guidelines without a specific citation in the provided text.

Key Pitfalls to Avoid

• Do not prescribe trazodone as monotherapy for primary chronic insomnia (strong recommendation) 2.
• Do not use benzodiazepines such as oxazepam for insomnia when safer alternatives exist (low‑strength recommendation) 1.
• Do not prescribe standard 3 mg eszopiclone doses to elderly patients; limit to 1–2 mg (moderate recommendation) 1.
• Do not combine trazodone with melatonin without evidence of benefit (moderate recommendation) 2.
• Do not continue ineffective therapy beyond 2–4 weeks without reassessment (moderate recommendation) 2.